• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cognition Therapeutics Inc.

    11/18/22 7:21:19 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGTX alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

      Cognition Therapeutics, Inc.  
      (Name of Issuer)  
         
      Common Shares  
      (Title of Class of Securities)  
         
      19243B102  
      (CUSIP Number)  
         
      November 10, 2022  
      (Date of Event Which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 19243B102

     

    1.

    Names of Reporting Persons. AIGH Capital Management, LLC

    I.R.S. Identification Nos. of above persons (entities only).

     

    27-4413262

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Maryland

    Number of Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

    Sole Voting Power

     

    2,037,853

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    2,037,853

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,037,853

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    7.0%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

     
     

     

    CUSIP No. 19243B102

     

    1.

    Names of Reporting Persons. Orin Hirschman

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    United States

    Number of Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

    Sole Voting Power

     

    2,037,853

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    2,037,853

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,037,853

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    7.0%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     
     

     

    ITEM 1:

     

    (a) Name of Issuer:

     

    COGNITION THERAPEUTICS, INC

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    2500 Westchester Ave.

    Purchase, NY 10577

     

    ITEM 2:

     

    (a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

      (i)   AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH LP”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P. and WVP Emerging Manger Onshore Fund, LLC;
         
      (ii)   AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;
         
      (iii)   Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock indirectly held by AIGH LP, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b) Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners, LP, AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

    (c) Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

    (d) Title of Class of Securities:

     

    Common Stock

     

    (e) CUSIP Number:

     

    19243B102

     

     
     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
           
         

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4: OWNERSHIP.

     

    See Item s 5,6,7,8 and 9 of each cover page.

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10: CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 18, 2022 By: /s/ Orin Hirschman
        Orin Hirschman,
        Individually and as (a) managing member of AIGH Capital Management LLC.: and (b) president of AIGH Investment Partners LLC.  

     

     

     

    Get the next $CGTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGTX

    DatePrice TargetRatingAnalyst
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    11/3/2021$27.00Buy
    B. Riley Securities
    11/3/2021$22.00Outperform
    Oppenheimer
    More analyst ratings

    $CGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Caggiano Anthony was granted 65,000 shares and covered exercise/tax liability with 20,281 shares, increasing direct ownership by 11% to 463,273 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    7/31/25 4:24:07 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Doyle John Brendan was granted 30,000 shares and covered exercise/tax liability with 9,360 shares, increasing direct ownership by 5% to 425,350 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    7/31/25 4:23:52 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO & President Ricciardi Lisa was granted 75,000 shares and covered exercise/tax liability with 23,400 shares, increasing direct ownership by 6% to 938,666 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    7/31/25 4:23:32 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

    - Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, received final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the end-of-Phase 2 meeting that was conducted on July 9, 2025. FDA confirmed the proposed design of the Phase 3 program may support a New Drug Application (NDA) filing for zervimesine (CT1812) as a treatment for Alzheimer's disease. Based on the FDA's feedback, the Phase 3 program is expected to enroll adults with a diagnosi

    8/12/25 4:00:25 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

    - Discussed plans to support a pivotal Alzheimer's disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START' study of zervimesine in early Alzheimer's disease - PURCHASE, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "The second quarter of 2025 has been very productive, with milestones from

    8/7/25 4:00:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

    - Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment -- Plasma and CSF biomarkers support zervimesine's impact on Alzheimer's disease biology - PURCHASE, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, presented results from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the Alzheimer's Association International Conference (AAIC 20

    7/29/25 7:30:23 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    SEC Filings

    View All

    Cognition Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

    8/7/25 5:16:41 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Cognition Therapeutics Inc.

    10-Q - COGNITION THERAPEUTICS INC (0001455365) (Filer)

    8/7/25 4:17:16 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

    6/20/25 4:01:35 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Ricciardi Lisa covered exercise/tax liability with 28,960 shares, was granted 631,300 shares and bought $30,001 worth of shares (38,851 units at $0.77), increasing direct ownership by 207% to 893,685 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/4/25 4:11:53 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ricciardi Lisa bought $9,975 worth of shares (5,700 units at $1.75), increasing direct ownership by 2% to 291,345 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    3/14/24 4:34:10 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cognition Therapeutics upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

    12/19/24 7:33:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral

    7/30/24 6:19:11 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Cognition Therapeutics with a new price target

    B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00

    11/3/21 8:37:44 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

    PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard

    5/1/23 7:30:44 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

    PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,

    10/11/22 8:00:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

    PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c

    11/3/21 8:00:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cognition Therapeutics Inc. (Amendment)

    SC 13G/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

    2/7/24 7:01:44 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cognition Therapeutics Inc.

    SC 13G - COGNITION THERAPEUTICS INC (0001455365) (Subject)

    1/19/24 3:07:49 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Cognition Therapeutics Inc. (Amendment)

    SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)

    11/13/23 5:25:24 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

    - Discussed plans to support a pivotal Alzheimer's disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START' study of zervimesine in early Alzheimer's disease - PURCHASE, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "The second quarter of 2025 has been very productive, with milestones from

    8/7/25 4:00:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

    - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimer's disease and dementia with Lewy bodies (DLB

    5/7/25 7:30:15 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

    Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year en

    3/20/25 7:00:26 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care